For all press and media enquiries please contact mediarelations@chiesi.com
International biopharmaceutical leader accelerates digital transformation with AI-powered customer engagement, unified data, and next-generation integration capabilities APRIL 20, 2026 – Chiesi Group, an international biopharmaceutical group, has selected Salesforce’s Agentforce Life Sciences for…
Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion, with European Commission (EC) decision anticipated by June 1, 2026 If approved, this would expand the indication of lomitapide to include children 5 years of age and older with HoFH PARMA, Italy – March 30, 2026 –…
Approved dosing regimen reduces the burden for eligible patients, their families, and the broader healthcare system by extending infusion interval from every-two-weeks to every-four-weeks for those stable with an enzyme replacement therapy (ERT) With this decision, announced ahead of Fabry Disease…
Highlights Agreement builds on existing Chiesi-Bespak collaboration, reinforcing a trusted relationship as Chiesi works to evolve a portfolio of extrafine formulation Carbon Minimal Inhalers [1], ensuring patients retain continuity of care while reducing carbon emissions Bespak’s leadership in…
Committee for Medicinal Products for Human Use (CHMP) issues a positive opinion following re-examination, which will be reviewed by the European Commission (EC), with a decision anticipated by March 2026 If approved by the EC, this dosing regimen would reduce the burden to eligible patients, their…
Key Highlights The two studies presented at BTS demonstrated therapeutic equivalence and similar safety profiles of Chiesi’s beclometasone dipropionate/ formoterol fumarate product formulated with next generation HFA-152a propellant, compared to the current HFA-134a formulation, in two different…
PARMA, Italy - Nov. 12, 2025 – Chiesi Group today announced it has entered into an exclusive license agreement with Aliada Therapeutics, a wholly owned subsidiary of AbbVie, to advance blood-brain barrier (BBB)-crossing platform technology in lysosomal storage disorders (LSD) to address challenging…
November 4, 2025– La Chaussée-Saint-Victor (France) – Today, the biopharmaceutical group Chiesi, a major player in the treatment of respiratory diseases, inaugurated the expansion of its industrial site located in La Chaussée-Saint-Victor, near Blois, in France. For Chiesi, improving patient health…
Exclusive collaboration and license agreement for the development and global commercialization of Arbor’s clinical-stage gene editing program, ABO-101 for primary hyperoxaluria type 1 (PH1) Multitarget research collaboration and option agreement for Arbor’s innovative gene editing technologies for…
You are leaving the Chiesi Corp site to access another Chiesi site. Regulatory constraints and medical practices, as well as the information published on the site you are about to visit, may change from one country to another and may not comply with current Italian legislation on the subject.
You are about to leave our website and access an external site. By continuing, you agree to leave our site.
